Usefulness of daily folic acid supplementation during methotrexate treatment of Japanese patients with rheumatoid arthritis

被引:7
作者
Sasaki, Keiichi [1 ]
Tsuji, Toshikazu [2 ]
Kimoto, Yasutaka [3 ]
Yanagihara, Yuki [1 ]
Masuguchi, Ken [1 ]
Chikamori, Ayako [1 ]
Watanabe, Hiroyuki [2 ]
Murakami, Tesshin [3 ]
Oryoji, Daisuke [3 ]
Hashimoto, Masafumi [1 ]
Horiuchi, Takahiko [3 ]
Egashira, Nobuaki [2 ]
机构
[1] Kyushu Univ, Beppu Hosp, Dept Pharm, Oita, Japan
[2] Kyushu Univ Hosp, Dept Pharm, Fukuoka, Japan
[3] Kyushu Univ, Beppu Hosp, Dept Internal Med, Oita, Japan
关键词
Rheumatoid arthritis; methotrexate; daily folic acid supplementation; toxicity; efficacy; LOW-DOSE METHOTREXATE; DOUBLE-BLIND; EFFICACY; MORTALITY; TOXICITY; RISK;
D O I
10.1080/14397595.2020.1743493
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: We investigated the effect of daily folic acid supplementation on methotrexate (MTX) toxicity and efficacy in Japanese patients with rheumatoid arthritis (RA). Methods: We followed 19 patients treated with MTX who switched from taking weekly 5 mg folic acid supplementation (weekly regimen) to 1.25 mg daily (daily regimen). White blood cell (WBC) and platelet (PLT) counts, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels were collected for 24 weeks following the change. Results: We observed no significant changes in WBC or PLT counts. AST and ALT levels, which had exceeded the upper limits of their normal ranges at the beginning of the study, were improved significantly at weeks 4 and 8, no subsequent deterioration in liver function was found. Further, no significant changes in ESR and CRP levels were observed. Conclusion: Our data indicate that supplementing 1.25 mg of folic acid daily rather than 5 mg weekly reduces toxicity caused by MTX without affecting its efficacy.
引用
收藏
页码:108 / 113
页数:6
相关论文
共 29 条
[1]  
Aletaha D, 2002, J RHEUMATOL, V29, P1631
[2]  
BLEYER WA, 1978, CANCER-AM CANCER SOC, V41, P36, DOI 10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO
[3]  
2-I
[4]  
Bressolle E, 2000, J RHEUMATOL, V27, P2110
[5]   Methotrexate and mortality in patients with rheumatoid arthritis:: a prospective study [J].
Choi, HK ;
Hernán, MA ;
Seeger, JD ;
Robins, JM ;
Wolfe, F .
LANCET, 2002, 359 (9313) :1173-1177
[6]   Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases [J].
Cronstein, Bruce N. ;
Sitkovsky, Michail .
NATURE REVIEWS RHEUMATOLOGY, 2017, 13 (01) :41-51
[7]   LONG-TERM REMISSIONS IN CHILDHOOD ACUTE LEUKEMIA - USE OF INFREQUENT INFUSIONS OF METHOTREXATE - SUPPORTIVE ROLES OF PLATELET TRANSFUSIONS AND CITROVORUM FACTOR [J].
DJERASSI, I ;
ABIR, E ;
ROYER, GL ;
TREAT, CL .
CLINICAL PEDIATRICS, 1966, 5 (08) :502-&
[8]   A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis [J].
Emery, P ;
Breedveld, FC ;
Lemmel, EM ;
Kaltwasser, JP ;
Dawes, PT ;
Gömör, B ;
Van den Bosch, F ;
Nordström, D ;
Bjorneboe, O ;
Dahl, R ;
Horslev-Petersen, K ;
de la Serna, AR ;
Molloy, M ;
Tikly, M ;
Oed, C ;
Rosenburg, R ;
Loew-Friedrich, I .
RHEUMATOLOGY, 2000, 39 (06) :655-665
[9]  
FURST DE, 1989, J RHEUMATOL, V16, P313
[10]   Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan [J].
Ishiguro, Seiji ;
Inoue, Manami ;
Tanaka, Yasuhito ;
Mizokami, Masashi ;
Iwasaki, Motoki ;
Tsugane, Shoichiro .
EUROPEAN JOURNAL OF CANCER PREVENTION, 2009, 18 (01) :26-32